阿托伐他汀钙联合缬沙坦对慢性肾炎患者的疗效研究

Research on Curative Effect of Atorvastatin Calcium Combined with Valsartan in Patients with Chronic Nephritis

目的分析慢性肾炎患者临床治疗中,采用阿托伐他汀钙、缬沙坦联合用药下取得的效果。方法收集2017年2月—2018年2月收治的慢性肾炎患者86例,借助数字随机分组方式,给予常规治疗配合缬沙坦的43例纳入到对照组,常规治疗基础上采用缬沙坦、阿托伐他汀钙联合用药治疗的43例纳入观察组,对两组患者治疗效果、肾功能、血脂指标观察,并比较两组患者用药安全性。结果治疗效果观察,治疗有效率观察组95.35%,对照组81.40%,组间对比差异有统计学意义(χ~2=4.07,P<0.05)。肾功能指标观察,治疗前患者CRP、BUN与Scr指标组间比较差异无统计学意义(P>0.05),治疗后各指标观察组改善均较为明显,与对照组组间差异有统计学意义(P<0.05)。血脂指标观察,同组患者治疗后TC、TG、HDL、LDL血脂指标与治疗前比较均差异有统计学意义(P<0.05),观察组与对照组组间各指标比较差异无统计学意义(P>0.05)。不良反应发生率观察组2.33%(1/43),对照组4.65%(2/43),组间对比差异无统计学意义(χ~2=0.35,P>0.05)。结论慢性肾炎患者临床治疗中,基础治疗的同时,联合用药缬沙坦、阿托伐他汀钙,对提高患者治疗效果、肾功能、血脂相关指标的改善有积极作用,应在临床实践中应用推广。

Objective To analyze the curative effect of atorvastatin calcium combined with valsartan in patients with chronic nephritis. Methods 86 cases of patients with chronic nephritis admitted in our hospital from February 2017 to February 2018 were selected and randomly divided into two groups with 43 cases in each, the control group used the routine therapy combined with valsartan, while the control group were treated with atorvastatin calcium combined with valsartan on the basis of the control group, and the treatment effect, renal function, blood liquid and medication safety were compared between the two groups. Results The treatment effective rate in the observation group and in the control group was respectively 95.35%a and 81.40%, and the difference was statistically signifant（χ~2=4.07, P0.05）, and there were no obvious differences in the CRP, BUN, Scr before treatment, after treatment, the improvement of various indicators was obvious, and the differences between the two groups were statistically signifant（P0.05）. The differences in the TC, TG, HDL, LDL blood liquid levels before and after treatment were statistically signifant（P0.05）, and the differences in various indicators between the two groups were not statistically signifant, and the incidence rate of adverse reactions in the observation group and in the control group was respectively 2.33%（1/43） and 4.65%（2/43）, and the difference was not statistically signifant（χ~2=0.35, P0.05）. Conclusion The atorvastatin calcium combined with valsartan in patients with chronic nephritis on the basis of the basic therapy can have a positive effect on improving the treatment effect, renal function and blood liquid related indicators, which should be applied and promoted in clinical practice.